Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings
OPTIMIZE was a randomized, open label study, which included 330 patients with chronic kidney disease (CKD) on dialysis with hyperphosphatemia. The study was designed to evaluate different methods of ...
Unicycive Therapeutics reports FY24 EPS (56c), consensus (51c)
Try Now>> See today’s best-performing stocks on TipRanks Unicycive Therapeutics NewsMORE Related Stocks Indices Commodities Currencies Stocks ...